SCHEMBL4568520

SCHEMBL4568520

CCOc1cc2[nH]c(-c3ccccc3)c(Cc3cccc(C(=O)OC)n3)c2cc1F

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MGAM O43451 1/20 0.38
GRM5 P41594 1/20 0.38
PPARG P37231 2/20 0.38
MAPT P10636 1/20 0.38
ADORA2A P29274 1/20 0.38
MRGPRX4 Q96LA9 2/20 0.38
GABRP O00591 1/20 0.37
GABRD O14764 1/20 0.37
GABRA1 P14867 1/20 0.37
GABRB1 P18505 1/20 0.37
GABRG2 P18507 1/20 0.37
GABRB3 P28472 1/20 0.37
GABRA5 P31644 1/20 0.37
GABRA3 P34903 1/20 0.37
GABRA2 P47869 1/20 0.37
GABRB2 P47870 1/20 0.37
GABRA4 P48169 1/20 0.37
GABRE P78334 1/20 0.37
GABRA6 Q16445 1/20 0.37
GABRG1 Q8N1C3 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4568524 0.94 GRM5 (0.39) GRM5MAPTADORA2AMRGPRX4KDM4E
SCHEMBL4568580 0.92 PPARG (0.41) MGAMPPARGMAPT
SCHEMBL4568506 0.91 MTNR1A (0.41) GRM5ADORA2AMRGPRX4TLR8TLR7
SCHEMBL4568525 0.90 MRGPRX4 (0.44) MGAMGRM5PPARGMAPTMRGPRX4
SCHEMBL4568519 0.89 TUBB4A (0.40) GRM5MAPTADORA2AMRGPRX4GABRP
SCHEMBL15998627 0.89 PPARG (0.37) MGAMPPARGMAPT
SCHEMBL4568513 0.88 PDE10A (0.43) TLR8TLR7KDM4EALDH1A1CYP1A2
SCHEMBL4568504 0.88 MAPT (0.41) MAPTKDM4EALDH1A1CYP1A2HPGD
SCHEMBL4568469 0.87 PARP1 (0.42) MAPTADORA2AMRGPRX4GABRPGABRD
SCHEMBL4568581 0.87 PDE10A (0.38) PPARGMAPTKDM4EALDH1A1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120122931-A1 INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF KISSEI PHARMACEUTICAL CO., LTD. (JP) 2012-05-17 US disclosed
US-20120122931-A1 INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF KISSEI PHARMACEUTICAL CO., LTD. (JP) 2012-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120122931-A1 INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF PTGER1, CYSLTR1, LTB4R MGAM 4713/4885GRM5 534/4885PPARG 500/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.